Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of the Lung 1Skin Neoplasms 1Osteosarcoma 1Melanoma 1Breast Neoplasms 1

Interventions

Ifosfamide 11Methotrexate 9Doxorubicin 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Leucovorin 5Etoposide 5X-Rays 4Specimen Handling 4Sirolimus 4Phantoms, Imaging 4Gemcitabine 4temsirolimus 3sargramostim 3dinutuximab 3cixutumumab 3Radiotherapy 3Nuclear Medicine Department, Hospital 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexrazoxane 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2samarium Sm-153 lexidronam 2palbociclib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Osteosarcoma × glembatumumab vedotin × Clear all
NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 15 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡